With GLP-1 drugs suppressing appetite, its no surprise that users are shifting their dining habits
If you are currently taking a GLP-1, you know exactly what Im talking about
Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress
Compared to dulaglutide, tirzepatide at both 5 and 10 mg doses has shown improved glycemic control as well as weight management with similar levels of tolerability
Whether you are needing to stop GLP-1 therapy due to adverse effects, contraindication or perhaps because you have reached your goal weight, there are proactive steps you can take to reduce the risk of rebound weight gain
In fact, a significant proportion of heavy drinkers are malnourished and may become more malnourished if they take GLP-1s to tackle their alcohol drinking